Cargando…
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections
BACKGROUND: Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials. Eravacycline, a novel member of the fluorocycline family, is active against multidrug-resistant bacteria including extended-spectru...
Autores principales: | Solomkin, Joseph S, Gardovskis, Janis, Lawrence, Kenneth, Montravers, Philippe, Sway, Angie, Evans, David, Tsai, Larry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735687/ https://www.ncbi.nlm.nih.gov/pubmed/30561562 http://dx.doi.org/10.1093/cid/ciy1029 |
Ejemplares similares
-
1963. Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacycline in the Treatment of Complicated Intra-abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4
por: Newman, Joseph, et al.
Publicado: (2018) -
Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials
por: Asempa, Tomefa E, et al.
Publicado: (2020) -
1978. Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection
por: Lawrence, Kenneth, et al.
Publicado: (2018) -
Burden of surgical site infection following cesarean section in sub-Saharan Africa: a narrative review
por: Sway, Angie, et al.
Publicado: (2019) -
1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)